

# Programme

---

**Wed 23 Oct**

11:50

Oral presentation

## **NIDA International Program Research Update**

11:50 to 13:20  
Auditorium VI  
Tom Clarke

Oral presentation

## **Managing Benzodiazepine Dependence and High-Risk Use with Opiates: A feasibility study of a Co- produced Intervention**

11:50 to 13:20  
Auditorium II  
Catriona Matheson

Oral presentation

## **Treatment of benzodiazepine withdrawal through taper dosing is most successful when it lasts less than 6 months.**

11:50 to 13:20  
Auditorium II  
Alert Drishti

Oral presentation

## **Understanding the research capacity of Australian alcohol and other drug services**

11:50 to 13:20  
Auditorium VI  
Robert Stirling

Oral presentation

## **Report from LX24 side event - Strengthening networks and sharing innovation in practices on**

Oral presentation

## **The effectiveness of naloxone in reversing opioid overdose: The European naloxone**

Oral presentation

## **A global perspective on the emotions associated with chemsex practice to better support the community**

**research and surveillance in the drugs field**

11:50 to 13:20  
Auditorium VI  
Vickna Kasinather  
Charles Parry

**outcome research study (NalPORS)**

11:50 to 13:20  
Auditorium II  
Nicola Metrebian

11:50 to 13:20  
Auditorium IV  
Yannick Gaudette

**Oral presentation**

**Addiction and financial burden: Longitudinal 6-time point analysis of risk factors for debt enforcement in Finland**

11:50 to 13:20  
Room 5B  
Atte Oksanen

**Oral presentation**

**Addressing gender, diversity, and precarity: participatory research to transform addiction services in Canada**

11:50 to 13:20  
Auditorium IV  
Karine Bertrand

**Oral presentation**

**Bipolar disorder and severe poisoning due to medicines or illicit substances**

11:50 to 13:20  
Auditorium VII  
Aleksi Hamina

**Oral presentation**

**Bringing law enforcement officers (LEO) closer to other agents of prevention: A UNODC Guiding Document**

11:50 to 13:20  
Room 5A  
Ali Yassine

**Oral presentation**

**Chemsex Professional Training Program in Catalonia**

11:50 to 13:20  
Auditorium IV  
Elena Adán Ibáñez

**Oral presentation**

**Children AMplified Prevention Services (CHAMPS): Amplify Children Resilience through a comprehensive prevention system**

11:50 to 13:20  
Room 5A  
Ali Yassine

Oral presentation

**Cultural safety and telecare. A systematic scoping review and sector survey**

11:50 to 13:20  
Auditorium III  
Rodrigo Ramalho

Oral presentation

**Drug Consumption Rooms in Europe. Operational characteristics, capacities, services and its associated factors.**

11:50 to 13:20  
Auditorium III  
Joana Moura

Oral presentation

**Enhanced self-efficacy in HCV management: educating a multidisciplinary drug and alcohol workforce in Europe and Canada**

11:50 to 13:20  
Room 5C  
Emma Day

Oral presentation

**Enhancing Capacity for Comprehensive Drug Use Response in Humanitarian Settings**

11:50 to 13:20

Oral presentation

**Exploring Australian addiction workers' views on inclusive treatment for transgender and gender diverse (TGD) clients.**

11:50 to 13:20  
Room 5C  
Nic Robinson-Griffith

Oral presentation

**Foundations of Prevention Science and Practice Curriculum: Providing Technical Assistance through Training**

11:50 to 13:20  
Room 5C  
Maria Paula Luna Jimenez

Oral presentation

**Gambling Disorder and Work Disability: A National Registry Study in Sweden**

11:50 to 13:20  
Room 5B  
Viktor Mansson

Oral presentation

**Hazardous substance use and mental health among refugees in shared accommodations - a mixed-methods study**

11:50 to 13:20  
Auditorium VII  
Miriam Lorenz

Oral presentation

**Lisdexamfetamine in the treatment of methamphetamine dependence, a randomised controlled trial**

11:50 to 13:20  
Auditorium II  
Nadine Ezard

Oral presentation

**Modelling the wider socio-economic costs of problematic opioid use in the UK**

11:50 to 13:20  
Auditorium VIII  
George Keel

Oral presentation

**Prevalence of opioid dependence in Scotland, 2015-2020: results from a Multi Parameter Estimation of Prevalence model**

11:50 to 13:20  
Auditorium VIII  
Hayley Jones

Oral presentation

**Problem Gambling Among Criminal Sanction Clients: Project Overview**

11:50 to 13:20  
Room 5B  
Sari Castrén

Oral presentation

**Scaling up Harm Reduction: Results of the 3-year Take-Home Naloxone project NALtrain in Germany.**

11:50 to 13:20  
Room 5C  
Simon Fleißner

Oral presentation

**Substance Use, Sexual Pleasure and Recovery among gbMSM: Addressing Sexual Satisfaction in Addiction Interventions**

11:50 to 13:20  
Auditorium IV  
Maxime Blanchette

Oral presentation

Oral presentation

Oral presentation

**Suicide-related service presentations following residential treatment for substance use disorders: a data linkage study**

11:50 to 13:20  
Auditorium VII  
Calvert Tisdale

Oral presentation

**The reciprocal effects of gambling expenditure and crime.**

11:50 to 13:20  
Room 5B  
Don Weatherburn

Oral presentation

**Twenty-one years of heroin-related mortality in Australia: Joinpoint regression analysis of trends by age and gender**

11:50 to 13:20  
Auditorium VIII  
Amanda Roxburgh

Oral presentation

**The gendered impacts of drug stigma - a qualitative study with 10 street-involved women who use drugs in Porto**

11:50 to 13:20  
Auditorium IV  
Cristiana Vale Pires

Oral presentation

**The role of physical activity in preventing relapse: the perception of participants**

11:50 to 13:20  
Auditorium III  
Florence Piché

Oral presentation

**Underestimate of deaths due to specific opioids in England and Wales for a decade**

11:50 to 13:20  
Auditorium VIII  
Shuoqi Chen

**The impact of severe mental illness on treatment retention and all-cause mortality of people in opioid agonist treatment**

11:50 to 13:20  
Auditorium VII  
Nicola Jones

Oral presentation

**The Staying Safe Programme: A new online education approach to reducing drug related harm for university students**

11:50 to 13:20  
Room 5A  
Adam Winstock

Oral presentation

**User experiences of a digital intervention among individuals on opioid use disorder treatment in Kenya**

11:50 to 13:20  
Auditorium III  
Sarah Kanana Kiburi

**“Good health has nothing to do with alcohol”: perceptions and impacts of a French alcohol prevention campaign**

11:50 to 13:20  
Room 5A  
Guillemette Quatremere

14:20

**Oral presentation**

**Engaging governments and providing technical assistance**

14:20 to 15:50  
Room 5C  
Goodman Sibeko

**Oral presentation**

**Why is a gender perspective needed in the drug field? Insight from the latest European drugs data.**

14:20 to 15:50  
Auditorium VIII  
Linda Montanari

**Oral presentation**

**Regional activity undertaken by the African Union**

14:20 to 15:50  
Room 5C  
Abel Basutu

**Oral presentation**

**Structure and predictive validity of alcohol use disorder recovery domains in young adulthood**

14:20 to 15:50  
Auditorium II  
George Richardson

**Oral presentation**

**An 11-year analysis of alcohol-related emergency**

**Oral presentation**

**Developing the Addiction Workforce in Africa:**

**Oral presentation**

**Building a substance use workforce network in**

**department presentations by young people, from an EU hospital setting**

14:20 to 15:50  
Auditorium II  
Marie Hyland

**Progress and Issues**

14:20 to 15:50  
Room 5C  
Kevin Mulvey

**Africa**

14:20 to 15:50  
Room 5C  
Rasha Abi Hana

**Oral presentation**

**Heavy episodic drinking among French adolescents between 2005 and 2022: a gender perspective.**

14:20 to 15:50  
Auditorium II  
Eric Janssen

**Oral presentation**

**Bridging the Gap: Exploring School Survey Data in Drug Policy and Prevention - Insights from the ESPAD-MedSPAD Project**

14:20 to 15:50  
Room 5A  
Elisa Benedetti

**Oral presentation**

**Changes in cannabis potency and cannabis-related harms: A 22-year ecological study in Denmark**

14:20 to 15:50  
Room 1.07  
Kristine Rømer Thomsen

**Oral presentation**

**Deficits in cognitive functions across different types of Internet-use disorders: Gender-related differences**

14:20 to 15:50  
Room 5B  
Silke M. Müller

**Oral presentation**

**Developing and operationalising a multi-component drug outreach service for young people aged 16-25 in England**

14:20 to 15:50  
Room 5A

**Oral presentation**

**Digital components in interventions aiming to reduce or prevent alcohol use among young people: A scoping review.**

14:20 to 15:50

**Oral presentation**

**Drug-induced homicide laws in the US: current trends, stakeholder opinions, and public health impacts**

14:20 to 15:50  
Auditorium VI  
Jennifer Carroll

**Oral presentation**

**Effect of acute stress on cue reactivity and craving in online buying-shopping disorder and social network use disorder**

14:20 to 15:50  
Room 5B  
Elisa Wegmann

**Oral presentation**

**Gender Compression Over Time in Measures of Cannabis Use by Age and Cohort in the United States**

14:20 to 15:50  
Auditorium VIII  
Michael Vuolo

**Oral presentation**

**Global coverage of interventions to prevent and manage injecting drug use related harms in prisons: a systematic review**

14:20 to 15:50  
Auditorium VI  
Thomas Santo Jr.

**Oral presentation**

**Judge Demographics and Their Impact on Sentencing of Drug Crimes**

14:20 to 15:50  
Auditorium IV  
Sarah Henry Davis

**Oral presentation**

**Levels of toxicants among people who vape, smoke, dual use, or do neither among people with and without psychosis.**

14:20 to 15:50

**Oral presentation**

**Leximetric analysis of drug laws and evaluation of outcomes: cross-country analyses approach**

14:20 to 15:50  
Auditorium IV  
Carla Rossi



Auditorium VII  
Eve Taylor

Oral presentation

**MATPACT: An innovative approach to finding Scotland's forgotten generation**

14:20 to 15:50  
Auditorium VI  
Marion Gillies

Oral presentation

**Navigating the Shift: Understanding the Dynamics of Cannabis Use in Germany Amidst Legalization Prospects**

14:20 to 15:50  
Auditorium IV  
Sally Olderbak

Oral presentation

**Pharmacology of generic ban-evading synthetic cannabinoid receptor agonists: are new compounds spicing up the market?**

14:20 to 15:50  
Room 1.07  
Marie Deventer

Oral presentation

**Policy and Practice Responses to Drug-Related Deaths: Governance issues in English and Welsh Prisons, 2015-2021**

14:20 to 15:50  
Auditorium VI  
Karen Duke

Oral presentation

**Proximal and distal cues in social network use disorder: the interplay of cue-reactivity, craving, and acute stress**

14:20 to 15:50  
Room 5B  
Annica Kessling

Oral presentation

**Psychological distress, tobacco**

Oral presentation

**Risk and protective factors in**

Oral presentation

**Risk factors for the gambling, smoking and**

**smoking and alcohol use: a population survey in Great Britain**

14:20 to 15:50  
Auditorium VII  
Erikas Simonavičius

**Oral presentation**

**Smokers' careers and mental health: overlapping perspectives on cannabis and tobacco use**

14:20 to 15:50  
Auditorium VII  
Joana Sisternas-Tusell

**Oral presentation**

**The Neurobiological and Neuropsychological Link Between Gambling Disorder and**

**adolescents: adapting Communities that Care Youth Survey for Portuguese context**

14:20 to 15:50  
Room 5A  
Susana Henriques

**Oral presentation**

**Smoking and nicotine use behaviours among women of reproductive age: a ten-year population study in England**

14:20 to 15:50  
Auditorium VIII  
Sharon Cox

**Oral presentation**

**The perspective of transsexual and non-binary people on their substance use trajectories**

**alcohol consumption triad: an observational study in Portuguese adolescents**

14:20 to 15:50  
Room 5A  
Pedro Ramos

**Oral presentation**

**The challenge of cannabis quantification: from theory to practice**

14:20 to 15:50  
Room 1.07  
Cláudia Sousa-Reis

**Oral presentation**

**The effects of legislative measures for 3-MMC in the Netherlands on drug sample composition and self-reported effects.**

14:20 to 15:50  
Auditorium IV  
Pieter Oomen

## **Substance Abuse**

14:20 to 15:50  
Room 5B  
Gisela Simões

## **and resilience processes**

14:20 to 15:50  
Auditorium VIII  
Abdelhakim Missoum

16:00

### **Oral presentation**

#### **Increased hepatitis C and HIV incidence among people who inject drugs in Montreal, Canada, 2011-2023**

16:00 to 17:30  
Auditorium IV  
Sarah Larney

### **Oral presentation**

#### **Alcohol Mis(Use) among Migrants, Asylum-seekers and Refugees: state-of-the-art**

16:00 to 17:30  
Auditorium II  
Maria Pires Cameira

### **Oral presentation**

#### **Canada synthetic opioids situation**

16:00 to 17:30  
Auditorium VIII  
Pam Kent

### **Oral presentation**

#### **Emerging drug trends - what are the issues and how can we strengthen preparedness**

16:00 to 17:30  
Auditorium VIII  
Paul Griffiths

### **Oral presentation**

#### **Harm reduction interventions and Indigenous peoples: The first Managed Alcohol Program in Montreal**

16:00 to 17:30  
Auditorium II  
Rossio Motta-Ochoa

### **Oral presentation**

#### **Predictors of outcome in individuals with alcohol use disorder and a treatment goal of controlled drinking**

16:00 to 17:30  
Auditorium II  
Anders Hammarberg

### **Oral presentation**

#### **The U.S. international perspective including the Global Coalition**

16:00 to 17:30  
Auditorium VIII  
Charlotte Sisson

### **Oral presentation**

#### **Crafting the international standard: Establishing and**

**implementing  
core outcome  
measures for  
alcohol brief  
interventions**

16:00 to 17:30  
Auditorium II  
Gillian W. Shorter

**Oral presentation**

**US experience  
with synthetic  
drugs**

16:00 to 17:30  
Auditorium VIII  
Christopher M. Jones

**Oral presentation**

**"Boxing  
Clever Cork  
saved my  
life": an  
evaluation of  
an Irish early  
addiction  
recovery  
initiative**

16:00 to 17:30  
Auditorium III  
Rebekah Brennan

**Oral presentation**

**A Safer  
Downtown for  
All: Including  
People Who  
Use Drugs in  
the Solutions  
to Social  
Disorder**

16:00 to 17:30  
Auditorium III  
Rob Boyd

**Oral presentation**

**Acute drug-  
toxicity  
presentations  
involving crack  
cocaine to  
Euro-DEN Plus  
sentinel  
hospitals in  
Europe from  
2014-2022**

16:00 to 17:30  
Room 5A  
Isabelle Giraudon

**Oral presentation**

**Antipsychotics  
and relapse  
risk in persons  
with first-  
episode  
psychosis and**

**Oral presentation**

**Associations of  
alcohol  
consumption  
with long-term  
mortality of  
ART-naïve**

**Oral presentation**

**Building  
Capacity For  
Future  
Evaluation of  
Residential  
Treatment for**

**co-occurring  
cannabis use  
disorder**

16:00 to 17:30  
Auditorium VII  
Heidi Taipale

Oral presentation

**Cannabinoid  
Use Experience  
among  
inpatients with  
psychotic  
symptoms - A  
Cross-Sectional  
study in a  
Portuguese  
Hospital**

16:00 to 17:30  
Auditorium VII  
Carolina Afonso Romano

Oral presentation

**Documenting  
major shifts in  
methamphetamine  
and heroin  
prices and  
purity in  
metropolitan  
and rural**

**persons  
seeking HIV  
care.**

16:00 to 17:30  
Auditorium IV  
Daniel Fuster

Oral presentation

**Challenges and  
support needs  
among persons  
with a  
migration  
background  
who use drugs  
in four  
metropolitan  
cities**

16:00 to 17:30  
Room 5C  
Wouter Vanderplasschen

Oral presentation

**Drug markets  
and financial  
flows:  
underground  
banking in the  
Netherlands**

16:00 to 17:30  
Auditorium VI

**People  
Experiencing  
Homelessness  
and Addiction**

16:00 to 17:30  
Auditorium III  
Ed Addison

Oral presentation

**Considering  
the prevention  
workforce: a  
study on  
practitioner  
needs when  
recommending  
substance use  
interventions**

16:00 to 17:30  
Room 1.06  
Natalie Blackburn

Oral presentation

**Decentralized  
consultation  
for infectious  
diseases with  
at-risk  
populations:  
preliminary  
results**

16:00 to 17:30  
Auditorium IV  
Paulo Caldeira

Oral presentation

**Drug poisoning  
deaths of  
under 30-year-  
olds - Key  
issues in the  
cause of death  
investigation  
documents**

## **Victoria, Australia**

16:00 to 17:30  
Auditorium VI  
Kasun Rathnayake

Nienke Liebrechts

16:00 to 17:30  
Room 5A  
Sanna Rönkä

### **Oral presentation**

**Drug use and  
(non-)use of  
addiction  
treatment by  
women in  
French  
Guyana:  
gender and  
migration  
effects**

16:00 to 17:30  
Room 5C  
Estelle Filipe

### **Oral presentation**

**Effects of  
recreational  
cannabis  
versus black  
market: A  
randomized  
controlled trial  
in Switzerland  
(WEED CARE)**

16:00 to 17:30  
Auditorium VI  
Lavinia Baltes

### **Oral presentation**

**Evaluating and  
comparing  
health quality  
for addiction  
treatment in  
the Lazio  
region, Italy**

16:00 to 17:30  
Room 1.06  
Antonella Camposeragna

### **Oral presentation**

**How do purity  
and price of  
cocaine affect  
consumption in  
Austria?**

16:00 to 17:30  
Auditorium VI  
Birgit Priebe

### **Oral presentation**

**How do you  
make it work?  
A pragmatic  
framework for  
the Sustained  
Uptake of  
Service  
Innovations  
(SUSI).**

16:00 to 17:30  
Room 1.06  
Catherine Foley

### **Oral presentation**

**Instruments  
assessing  
Gaming  
Disorder in  
children and  
adolescents - A  
systematic  
review of  
psychometric  
properties**

16:00 to 17:30  
Room 5B  
Samantha Schlossarek

### **Oral presentation**

### **Oral presentation**

### **Oral presentation**

Oral presentation

**Migrants in the criminal justice system: A qualitative understanding of the role of substance use in their lives**

16:00 to 17:30  
Room 5C  
Marjolein De Pau

Oral presentation

**Mortality among first-time opioid agonist therapy patients in Austria, 2002-2021: A national retrospective cohort study**

16:00 to 17:30  
Room 5A  
Tanja Schwarz

Oral presentation

**Mothers receiving substance use treatment involved in care proceedings: A record linkage cohort study**

16:00 to 17:30  
Room 5A  
Martha Canfield

Oral presentation

**Planning and Monitoring drug and alcohol treatment in Denmark. The MapPlan project.**

16:00 to 17:30  
Room 1.06  
Mads Uffe Pedersen

Oral presentation

**Psychoactive Substance Use Among Russian Migrants Relocated to Georgia Following the 2022 Ukrainian Invasion**

16:00 to 17:30  
Room 5C  
David Otiashvili

Oral presentation

**Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis**

16:00 to 17:30  
Auditorium VII  
Antti Mustonen

Oral presentation

**Refugees & drug use in Belgium: A national study on drug-related intervention needs in the reception setting (DrugInt)**

16:00 to 17:30  
Room 5C  
Charlotte de Kock

Oral presentation

Oral presentation

Oral presentation

**Screening Measures on Internet Use Disorders in Children and Adolescents - A Delphi Study**

16:00 to 17:30  
Room 5B  
Hans-Juergen Rumpf

**Superiority and cost-effectiveness of Individual Placement and Support for people with alcohol and drug dependence**

16:00 to 17:30  
Auditorium III  
John Marsden

**The Gaming Disorder Identification Test (GADIT) - A screening tool for Gaming Disorder based on ICD-11**

16:00 to 17:30  
Room 5B  
Gary Chan

**Oral presentation**

**The Problematic Behaviour Scale (PBS-10): psychometric characteristics and cut-offs using Swiss national survey data**

16:00 to 17:30  
Room 5B  
Sebastian Mader

**Oral presentation**

**“Into a whirlwind”: Navigating psychosis and anti-psychotic treatment among youth entrenched in an urban drug scene**

16:00 to 17:30  
Auditorium VII  
Trevor Goodyear

**Oral presentation**

**“They kicked me out of hospital twice”: barriers and facilitators accessing care with an injecting-related infection**

16:00 to 17:30  
Auditorium IV  
Samantha Colledge-Frisby



Oral presentation

**Application of the International Standards for the Treatment of Drug Use Disorders and the Key Quality Standards for service appraisal**

17:50 to 19:20  
Auditorium II  
Anja Busse

Oral presentation

**International Consortium on Quality in Substance Use Disorders Treatment**

17:50 to 19:20  
Auditorium II  
Rita Notarandrea

Oral presentation

**Insights from the Recipient of the first ICQ Quality Seal Award**

17:50 to 19:20  
Auditorium II  
Michael W. Johnson

Oral presentation

**PIQAT: Program for International Quality Assurance in Treatment**

17:50 to 19:20  
Auditorium II  
Mariano Montenegro

Oral presentation

**(De)criminalisation of drug possession as a litmus test of national drug policy? Experience from the Czech Republic**

17:50 to 19:20  
Auditorium VI  
Petr Zeman

Oral presentation

**20-year trends in Australian methamphetamine related deaths: An age-period-cohort-interaction analysis**

17:50 to 19:20  
Auditorium IV  
Oisin Stronach

Oral presentation

**A Collaborative Approach to New Drug Identification in an Emerging Drug Early Warning System**

17:50 to 19:20  
Auditorium III  
Donna Papsun

Oral presentation

**Achieving universal health coverage of opioid agonist treatment in Norway: a**

Oral presentation

**Adolescents spending time with their parents: does it matter to prevent risky and addictive**

## **cost-utility analysis**

17:50 to 19:20  
Room 5B  
Prayash Chaudhary

## **behaviors?**

17:50 to 19:20  
Room 5A  
Ina Koning

**Oral presentation**

## **AN IMPLEMENTATION SCIENCE EVALUATION OF SCOTLAND'S FIRST HEROIN ASSISTED TREATMENT (HAT) FACILITY**

17:50 to 19:20  
Room 5B  
Andrew McAuley

**Oral presentation**

## **Assessing quality of substance use treatment in legal settings: lessons from United States drug courts**

17:50 to 19:20  
Auditorium VI  
Steven Belenko

**Oral presentation**

## **Codeine, oxycodone, and tramadol prescription prior to overdose deaths compared to toxicological findings**

17:50 to 19:20  
Auditorium IV  
Hilde Edvardsen

**Oral presentation**

## **Comorbidity of substance use disorders and other mental health disorders: towards a common European approach**

17:50 to 19:20  
Auditorium VII  
Marta Torrens

**Oral presentation**

## **Development of a mobile neuroscience- informed psychoeducation program for resilience and substance use**

**Oral presentation**

## **Effects of cannabis use timing and formulation on sleep among young adults who report high-intensity**

**Oral presentation**

## **Emergence of semi-synthetic cannabinoids in Europe - a perspective from the European Union Early**

## **prevention**

17:50 to 19:20  
Room 5A  
Jasmin Vassileva

**Oral presentation**

### **Examining Associations Between Alcohol and Cannabis Simultaneous and Concurrent Co-Use and Mental Health Outcomes**

17:50 to 19:20  
Auditorium VII  
Bradley Conner

**Oral presentation**

### **Medical use of psychedelic substances: EUDA's monitoring of key developments**

17:50 to 19:20  
Auditorium VIII  
Alexander Söderholm

**Oral presentation**

## **alcohol use**

17:50 to 19:20  
Auditorium VII  
Elizabeth R. Aston

**Oral presentation**

### **Exploring social-environmental factors in recovery and reintegration of substance-related disorders: a scoping review**

17:50 to 19:20  
Room 5A  
Mariana Vieira

**Oral presentation**

### **Monitoring intravenous drugs use in Spain through syringe residue analysis**

17:50 to 19:20  
Auditorium IV  
Carlos Pernas-Fraguela

**Oral presentation**

## **Warning System**

17:50 to 19:20  
Auditorium III  
Rachel Christie

**Oral presentation**

### **Heavy drinking among 'sober generation' youth: a longitudinal study**

17:50 to 19:20  
Room 5C  
Marit Edland-Gryt

**Oral presentation**

### **Law Enforcement Encounters and Decriminalization Gaps: Insights from People Who Use Drugs in Oregon Post-Measure 110**

17:50 to 19:20  
Auditorium VI  
Morgan Godvin

**Oral presentation**

### **Motivations for cocaine use: relation with drug use patterns, risks and how this informs prevention**

17:50 to 19:20  
Room 5C  
Eva Blomme

**Oral presentation**

**Motivations underlying co-use of benzodiazepines and opioids in the UK: a qualitative study**

17:50 to 19:20  
Room 5C  
Gaby Vojt

**Parents aren't out of the picture: Parent factors are linked with heavy episodic drinking among high school students**

17:50 to 19:20  
Room 5A  
Lotte Vallentin-Holbech

**Police drug diversion in England and Wales: Findings from a realist process evaluation**

17:50 to 19:20  
Auditorium VI  
Alex Beerjeraz

**Oral presentation**

**Quantifying and expanding alternatives to arrest for use and possession offences for illicit drugs**

17:50 to 19:20  
Auditorium VI  
Caitlin Hughes

**Oral presentation**

**Reduced health care utilization after entering opioid agonist treatment; change in mental and somatic health domains**

17:50 to 19:20  
Room 5B  
Thomas Clausen

**Oral presentation**

**Route-Dependent Subjective Effects of Medical Heroin in HAT: Implications for Treatment Trajectories**

17:50 to 19:20  
Room 5B  
Silvana De Pirro

**Oral presentation**

**Synthetic cathinones in drug-related deaths - an alarming issue**

**Oral presentation**

**Self-therapeutic use of psilocybin, MDMA and ketamine among Dutch nightlife attendees.**

17:50 to 19:20  
Auditorium VIII  
Frederiek Schutten

**Oral presentation**

**The relationship between self-reported childhood**

## or triviality?

17:50 to 19:20  
Auditorium III  
Ilkka Ojanperä

## maltreatment and mental health in substance use disorders

17:50 to 19:20  
Auditorium VII  
Aleksander Hagen Erga

Oral presentation

### **The U.S. Psilocybin Landscape: Policy Evolution and Nationally Representative Insights**

17:50 to 19:20  
Auditorium VIII  
Beau Kilmer

Oral presentation

### **Trends in GHB use and harms in Australia**

17:50 to 19:20  
Auditorium III  
Rachel Sutherland

Oral presentation

### **What are the reasons for injecting methadone? A qualitative study among people who inject drugs in Barcelona**

17:50 to 19:20  
Auditorium IV  
Gabriela Barbaglia

Oral presentation

### **‘Russian Roulette’: how do people who co-use benzodiazepines and opioids experience the absence of harm reduction?**

17:50 to 19:20  
Room 5C  
Hannah Poulter

**Thu 24 Oct**

11:50

Oral presentation

### **Crisis in the race to**

Oral presentation

### **Long-acting injectable**

Oral presentation

### **Neurobiological Markers of**

**hepatitis C  
elimination:  
modelling  
futures without  
disease**

11:50 to 13:20  
Auditorium VIII  
Kari Lancaster

**buprenorphine  
for opioid use  
disorder: key  
findings from a  
longitudinal  
qualitative  
study**

11:50 to 13:20  
Auditorium IV  
Joanne Neale

**Alcohol Use  
Disorder:  
Implications  
for Prevention  
and Treatment**

11:50 to 13:20  
Auditorium II  
Jorge Martins

**Oral presentation**

**Identifying  
harmful alcohol  
use with  
phosphatidyletha  
16:0/18:1 in  
patients with  
suspected  
severe injury**

11:50 to 13:20  
Auditorium II  
Benedicte Joergenrud

**Oral presentation**

**Adapting  
Opioid  
Therapy:  
Transition from  
Methadone to  
Slow-Release  
Morphine Amid  
COVID-19  
Supply Chain  
Disruptions**

11:50 to 13:20  
Auditorium IV  
Artūras Barkus

**Oral presentation**

**Endgames:  
Disease  
eliminations  
and their  
politics**

11:50 to 13:20  
Auditorium VIII  
Tim Rhodes

**Oral presentation**

**VALIDATION OF  
PLASMA  
BIOMARKERS  
FOR  
PREDICTING  
AND  
PREVENTING  
ALCOHOL-  
ASSOCIATED  
RISK OF  
DEMENTIA:  
PRELIMINARY  
DATA**

11:50 to 13:20  
Auditorium II  
Fernando Rodriguez de  
Fonseca

**Oral presentation**

**A Global  
Perspective on**

**Oral presentation**

**A Holistic  
Multi-**

**Oral presentation**

**A wastewater-  
based**

## **Treatment Service Provision for Opioid Use Disorders**

11:50 to 13:20  
Auditorium III  
Arash Khojasteh Zonoozi

## **Disciplinary Healthcare Pathway for Older Men who use Anabolic Androgenic Steroids**

11:50 to 13:20  
Room 1.08  
Evelyn Hearne

## **approach to monitor shifting trends in illicit drugs consumption in Switzerland**

11:50 to 13:20  
Room 5A  
Livia Andrani

**Oral presentation**

## **Cannabis policy and practice in Finland: from social media discussions to citizens initiatives**

11:50 to 13:20  
Room 1.08  
Aleksi Hupli

**Oral presentation**

## **Clinicians' experience of providing heroin-assisted treatment: Key rewards and challenges**

11:50 to 13:20  
Room 5C  
Rune Ellefsen

**Oral presentation**

## **Drink and be merry? The impact of alcohol and affective social cues on emotional contagion**

11:50 to 13:20  
Auditorium II  
Rebecca Monk

**Oral presentation**

## **Drugs and climate change: knowledge gaps in monitoring environmental impacts of drugs**

11:50 to 13:20  
Room 1.08  
Tim Surmont

**Oral presentation**

## **European Hair Drug Analysis Network - A pioneer study to investigate the use of NPS**

**Oral presentation**

## **Fostering Community: A Mixed Method Analysis of Kosmicare's Mobile Drug**

**Oral presentation**

## **Health-related quality of life trajectories of patients in heroin-assisted treatment**

## **and NSO**

11:50 to 13:20  
Room 5A  
Elisa Fornero

## **Checking Service in Lisbon, Portugal**

11:50 to 13:20  
Room 5C  
Helena Valente

11:50 to 13:20  
Auditorium III  
Francesca Melis

### **Oral presentation**

## **Impact of long- acting depot buprenorphine post-release from custody- Early findings from the Release Study**

11:50 to 13:20  
Auditorium IV  
Adrian Dunlop

### **Oral presentation**

## **Key challenges for alcohol epidemiology and alcohol control policy evaluation**

11:50 to 13:20  
Auditorium VI  
Jürgen Rehm

### **Oral presentation**

## **Legally grey? Drug checking perspectives in the CEECA region**

11:50 to 13:20  
Auditorium VI  
Eliza Kurcevič

### **Oral presentation**

## **Opioid disorder treatment outcomes — the OPTIMUS international consensus on evidence- based and patient- centred care**

11:50 to 13:20  
Auditorium III  
Lucas Wiessing

### **Oral presentation**

## **Perceptions of family physicians in Istanbul on e- cigarettes as smoking cessation aids**

11:50 to 13:20  
Room 1.08  
Melis Selamoglu

### **Oral presentation**

## **Prevention of hazardous substance use among refugees - digital tools for the workforce in refugee aid**

11:50 to 13:20  
Room 5C  
Jonathan Uricher

### **Oral presentation**

## **Public health for whom? Unpacking the assumptions and silences in Canada's public health approach to substance use.**

11:50 to 13:20  
Auditorium VI  
Sophie Henderson



Oral presentation

**Synthesis of multisource data for the development of an advanced dashboard to monitor illicit drugs markets**

11:50 to 13:20  
Room 5A  
Pierre Esseiva

Oral presentation

**The Costs and Harms of Substance Use in Canada: Key Trends from 2007 to 2022**

11:50 to 13:20  
Auditorium VI  
Pam Kent

Oral presentation

**The situation of Harm Reduction in Spain: a qualitative approach including PWUD**

11:50 to 13:20  
Room 5C  
Ester Aranda

Oral presentation

**Trends in use of medicines for opioid agonist treatment in Australia, 2013-2022**

11:50 to 13:20  
Auditorium III  
Michael Farrell

Oral presentation

**What can Portugal do to prevent be caught off guard again in the drug domain?**

11:50 to 13:20  
Room 5A  
Alcina Correia

14:20

Oral presentation

**Practical overview of management including naloxone dosing. Illustration with cases related to potent synthetic opioids, St Thomas' hospital, 2023.**

14:20 to 15:50  
Auditorium VIII

Oral presentation

**Looking Ahead: Future Priorities for Cannabis Research, Public Education, and Prevention**

14:20 to 15:50  
Auditorium IV  
Shea Wood

Oral presentation

**Overview of the Cannabis Act and Cannabis Regulations**

14:20 to 15:50  
Auditorium IV  
Robert Gabrys

Oral presentation

**Post-mortem analytical findings and characteristics of the nitazene-**

## **related deaths cases, Finland, 2023**

14:20 to 15:50  
Auditorium VIII  
Kriikku Pirkko

Oral presentation

### **A Review of the Public Health and Safety Impacts of Cannabis of Legalization and Key Recommendations**

14:20 to 15:50  
Auditorium IV  
Justine Renard

Oral presentation

### **Acute drug toxicity outbreak with nitazenes involved in prison setting and the community, La Réunion, France, June-July 2023**

14:20 to 15:50  
Auditorium VIII  
Joris Guyon

Oral presentation

### **Acute nitazene-toxicity presentations to hospital emergency services, Dublin, Ireland, November 2023 outbreak**

14:20 to 15:50  
Auditorium VIII  
Adrian Moughty

Oral presentation

### **Dynamic associations between anxiety and alcohol use from early adolescence to young adulthood.**

14:20 to 15:50  
Auditorium VII  
Margot Peeters

Oral presentation

### **A mixed methods systematic review of interventions for women in the perinatal**

Oral presentation

### **A randomized controlled trial of support programs for parents of treatment-refusing**

Oral presentation

### **Associations between opioid agonist therapy exposure and chronic pain characteristics**

**period, who  
are dependent  
on drugs**

14:20 to 15:50  
Room 5B  
Emma Smith

**Oral presentation**

**Cannabis use  
disorder and  
the brain: The  
role of cross-  
cultural  
differences in  
cannabis  
attitudes**

14:20 to 15:50  
Auditorium III  
Janna Cousijn

**substance  
using young  
adults**

14:20 to 15:50  
Auditorium VII  
Ola Siljeholm

**Oral presentation**

**Community-  
wide effects of  
building a  
resilient  
community  
healthcare  
workforce**

14:20 to 15:50  
Room 5C  
Carol Jones

**among people  
who inject  
drugs**

14:20 to 15:50  
Auditorium VI  
Sasha Udhesister

**Oral presentation**

**Conceptualising  
the right to  
health in the  
context of the  
world drug  
problem**

14:20 to 15:50  
Auditorium VI  
Alison Ritter

**Oral presentation**

**Differential  
effects of left  
and right  
insula  
inhibition on  
craving and  
cognitive  
control in  
regular  
smokers**

14:20 to 15:50  
Auditorium III  
Mieke Schulte

**Oral presentation**

**Drug-related  
deaths among  
housed and  
homeless  
individuals in  
the UK and the  
USA**

14:20 to 15:50  
Auditorium IV  
Emmert Roberts

**Oral presentation**

**Drug-related  
mortality  
associated  
with  
gabapentinoid/  
Z-drug co-  
prescribing  
among opioid-  
agonist  
treatment**

**Oral presentation**

**EXPERIENCES  
OF DRUG  
CONSUMPTION  
ROOM  
PROFESSIONALS**

14:20 to 15:50  
Room 5C  
Patricia Domingos Belo

**Oral presentation**

## **recipients**

14:20 to 15:50  
Auditorium IV  
Megan Glancy

## **Female-specific trends and treatment needs for substance use disorder among homeless and at-risk females**

14:20 to 15:50  
Room 1.08  
Anne Marie Carew

**Oral presentation**

### **Gender and drugs: Experiences of stigma/toxicophobias and narcofeminist narratives**

14:20 to 15:50  
Room 1.08  
Marie Jauffret-Roustide

**Oral presentation**

### **High body mass index is prevalent in people with opioid use disorder in Northern England and increases risk of death**

14:20 to 15:50  
Auditorium IV  
Caroline Copeland

**Oral presentation**

### **Innovation in caring for individuals experiencing polydrug use disorder: opportunities to understand multi-morbidities**

14:20 to 15:50  
Room 5C  
Alexander Baldacchino

**Oral presentation**

### **International drug policy constellations: exploring the role of power and morality in international drug policy debates**

14:20 to 15:50  
Auditorium VI  
Alex Stevens

**Oral presentation**

### **Peripheral endocannabinoids and related lipids in individuals with chronic non-medical prescription opioid use**

14:20 to 15:50  
Auditorium III  
Sara Kroll

**Oral presentation**

### **Policy Responses to Drug-Related Deaths: The power of numbers?**

14:20 to 15:50  
Auditorium IV  
Lena Eriksson

**Oral presentation**

### **Policy responses to drug-related deaths: Using**

## **a Social Determinants of Health framework analysis to inform policy**

14:20 to 15:50  
Auditorium VI  
Aileen O'Gorman

**Oral presentation**

**Pregnancy-  
related  
hospitalisation  
among women  
who inject  
drugs in  
Melbourne,  
Australia**

14:20 to 15:50  
Room 5B  
Ashleigh Stewart

**Oral presentation**

**Squandered  
sexenio:  
applying drug  
policy  
constellations  
to the failure  
of marijuana  
legalization in  
Mexico (2018-  
2024)**

14:20 to 15:50  
Auditorium VI  
Jonas von Hoffmann

**Oral presentation**

**Substance use  
variation  
among LGBTQ+  
youth: stress,  
resilience and  
ecosystemic  
intervention**

14:20 to 15:50  
Auditorium VII  
Julie-Christine Cotton

**Oral presentation**

**The care  
pathways of  
women who  
use drugs in  
the perinatal  
period.  
Findings of a  
qualitative,  
longitudinal  
study**

14:20 to 15:50  
Room 5B  
Polly Radcliffe

**Oral presentation**

**The genetic  
etiology of  
cannabis use:  
from twin  
models to  
genome-wide**

**Oral presentation**

**The perinatal  
period as a  
window of  
opportunity for  
change and  
recovery? A**

**Oral presentation**

**Understanding  
substance use  
and affective  
symptoms in  
late  
adolescents in**

## **association studies and beyond**

14:20 to 15:50  
Auditorium III  
Karin J. H. Verweij

**Oral presentation**

### **Unveiling the Nexus of Addiction, Violence, and Risk: Generational Patterns in Female Populations**

14:20 to 15:50  
Room 1.08  
Sabrina Molinaro

## **study of mothers and relatives' accounts**

14:20 to 15:50  
Room 5B  
Sarah Vandewalle

**Oral presentation**

### **Vulnerabilities and agencies of women who use and sell drugs in Bordeaux and Montréal**

14:20 to 15:50  
Room 1.08  
Sarah Perrin

## **an urban context: A network approach**

14:20 to 15:50  
Auditorium VII  
Helle Larsen

**Oral presentation**

### **What do clinicians think about psychedelic assisted therapy? An Australian perspective.**

14:20 to 15:50  
Room 5C  
Zachary Bryant

16:00

**Oral presentation**

### **Experiences of building a Prompt Response Network for emerging drugs of concern in Australia**

16:00 to 17:30  
Room 1.05  
Brendan Clifford

**Oral presentation**

### **Psychosocial Care**

16:00 to 17:30  
Room 5C  
Paul O'Brien

**Oral presentation**

### **Emerging Drug trends in Japan: rethinking prevention strategies**

16:00 to 17:30  
Room 1.05  
Hironobu Fujiwara

**Oral presentation**

### **ACCS complexity of care provision**

16:00 to 17:30  
Room 5C  
Jacob Krzanowski

**Oral presentation**

### **Socioeconomic differences in the real-world effectiveness of pharmacotherapy of alcohol-related health problems**

16:00 to 17:30  
Auditorium II  
Devy Elling

Oral presentation

**The promised endings and missed targets of global disease elimination**

16:00 to 17:30  
Auditorium VIII  
Sarah Larney

Oral presentation

**Are the key impacts being measured? Hepatitis C elimination in Australia**

16:00 to 17:30  
Auditorium VIII  
Gregory Dore

Oral presentation

**Estimating the global burden of alcohol's harm to others**

16:00 to 17:30  
Auditorium II  
Anne-Marie Laslett

Oral presentation

**Exploring Novel Psychoactive Substances Among Kazakhstan's Youth: A Focus on Emerging Trends and Risks**

16:00 to 17:30  
Room 1.05  
Mariya Prilutskaya

Oral presentation

**The Addiction Clinical Care Suite (ACCS): service outline and 2 year outcome data**

16:00 to 17:30  
Room 5C  
John Archer

Oral presentation

**Background and establishment of the Addiction Clinical Care Suite (ACCS): a comprehensive, multi-disciplinary inpatient addiction service in London**

16:00 to 17:30  
Room 5C  
Shantelle Quashie

Oral presentation

**Economic wealth, patterns of drinking, and alcohol-attributable disease burden**

16:00 to 17:30  
Auditorium II  
Pol Rovira

Oral presentation

**The case of Kratom: from traditional medical to recreational**

## **use**

16:00 to 17:30  
Room 1.05  
Vicknasingam Balasingam

### **Oral presentation**

**25 years of monitoring the Dutch cannabis market using chemical analysis: trends, developments and technical discussion**

16:00 to 17:30  
Room 1.08  
Pieter Oomen

### **Oral presentation**

**A comparative analysis of state-controlled models for legal cannabis sales in Uruguay and Quebec (Canada)**

16:00 to 17:30  
Auditorium VI  
Marta Rychert

### **Oral presentation**

**A national program to scale-up decentralized HCV point-of-care testing and treatment in Australia**

16:00 to 17:30  
Auditorium IV  
Jason Grebely

### **Oral presentation**

**A provisional evaluation of Australia's medical cannabis framework**

16:00 to 17:30  
Auditorium VI  
Myfanwy Graham

### **Oral presentation**

**Adverse childhood experiences and drug use in early adulthood: an analysis of the Growing Up in Ireland 1998 cohort**

16:00 to 17:30  
Room 5A  
Deirdre Mongan

### **Oral presentation**

**Biography, age and temporality: understanding shifts in alcohol consumption over time among young abstainers**

16:00 to 17:30  
Room 5A  
Amy Pennay

### **Oral presentation**

**Brorphine analogues as new psychoactive substances: in vitro and in vivo pharmacological characterization**

16:00 to 17:30  
Auditorium III  
Marthe Vandeputte

### **Oral presentation**



## **Consequences of cannabis legalization on use and health outcomes on the basis of international experiences**

16:00 to 17:30  
Auditorium VI  
Uwe Verthein

**Oral presentation**

**Dropout from addiction treatment: predictors, patient profiles, outcomes, and recommendations to improve care.**

16:00 to 17:30  
Auditorium VII  
Marie-Josée Fleury

**Oral presentation**

**Drug monitoring by samples seized at 2018, 2022 and 2023 BOOM festival editions**

16:00 to 17:30  
Room 1.08  
Carla Filipa Ferreira

**Oral presentation**

**Factors associated with cocaine use in late adolescence and young adulthood in the Growing Up in Ireland cohort study**

16:00 to 17:30  
Room 5A  
Margaret Brennan

**Oral presentation**

**HCV Community-led monitoring: from consultation to effective policy contributions**

16:00 to 17:30  
Auditorium IV  
Lynn Jefferys  
Joana Canedo

**Oral presentation**

**In vitro cannabinoid activity-based screening of seized plant materials: a future-proof harm reduction strategy?**

16:00 to 17:30  
Auditorium III  
Axelle Timmermann

**Oral presentation**

**LECUCA: Analysis of Brazil's largest open drug scene using time-series cross-sectional survey data**

16:00 to 17:30  
Room 1.08  
Clarice Madruga

**Oral presentation**

**Modelling the impact of**

**Oral presentation**

**Neurotoxicity of synthetic**

**Oral presentation**

**Online Addictions**

**scaling up of  
HCV case  
finding and  
treatment for  
people who  
inject drugs in  
England**

16:00 to 17:30  
Auditorium IV  
Zoe Ward

**cathinones:  
Can  
metabolism  
play a role?**

16:00 to 17:30  
Auditorium III  
Alexandra Antunes

**Expert Group  
of the  
Pompidou  
Group: Results  
and  
Recommendations**

16:00 to 17:30  
Room 5B  
Jann Schumacher

**Oral presentation**

**Oral presentation**

**Pharmacology  
of 30  
semisynthetic  
cannabinoids -  
and why  
details matter  
when  
assessing the  
harm potential  
of seized drugs**

16:00 to 17:30  
Auditorium III  
Christophe Stove

**Pilot HCV Birth  
Cohort  
Screening in  
UK Primary  
Care using a  
postal oral  
fluid home  
testing kit: the  
HEPCAPP  
StudyPP  
STUDY**

16:00 to 17:30  
Auditorium IV  
Matt Hickman

**Oral presentation**

**Oral presentation**

**Oral presentation**

**Prevention  
when exclusion  
is lifted:  
Intervention  
models from  
the New Swiss  
Gambling Act**

16:00 to 17:30  
Room 5B  
Linda Elezi

**Risks and  
harms  
associated  
with online  
gaming and  
gambling**

16:00 to 17:30  
Room 5B  
Eduarda Ferreira

**Same  
Intentions,  
Different  
Outcomes:  
Divergent  
Paths and  
Implementation  
Gaps in  
Cannabis  
Legalization in  
North America**

16:00 to 17:30  
Auditorium VI  
Ivana Obradovic

**Oral presentation**

**Oral presentation**

**Oral presentation**

**Service user**

**The end of**

**The use of**

**and Carer  
perspective on  
Treatment for  
Co-Occurring  
Mental Health  
and Substance  
Use Problems  
(RECO Study)**

16:00 to 17:30  
Auditorium VII  
Elizabeth Hughes

**responsible  
gambling**

16:00 to 17:30  
Room 5B  
Charles Livingstone

**patient-  
reported  
outcomes in  
residential  
alcohol &  
drug services  
in Belgium:  
findings from  
the OMER-BE  
study**

16:00 to 17:30  
Auditorium VII  
Amine Zerrouk

**Oral presentation**

**Trends in illicit  
and licit  
substance use  
across Spain -  
A  
comprehensive  
three-year  
wastewater-  
based  
epidemiology  
study.**

16:00 to 17:30  
Room 1.08  
José Benito Quintana

**Oral presentation**

**Who is driving  
under the  
influence of  
cannabis in  
Germany?  
Findings of a  
large-scale  
online survey**

16:00 to 17:30  
Room 5A  
Anna Schranz

17:50

**Oral presentation**

**Age-related  
loss of  
autonomy,  
residential  
instability and  
alcohol use:  
suggestions to  
improve  
intervention  
and services**

17:50 to 19:20  
Auditorium VI

**Oral presentation**

**Epidemiology  
of injecting  
drug use and  
injection  
related harms  
among people  
who are  
incarcerated**

17:50 to 19:20  
Auditorium IV  
Louisa Degenhardt

**Oral presentation**

**Exploring  
drinking  
motives and  
alcohol  
consumption in  
a UK LGBTQ+  
population**

17:50 to 19:20  
Auditorium II  
Adam Qureshi

**Oral presentation**

## **Illustrating the Recovery Journey: Exploring Women's Alcohol Treatment Experiences Through Participant Drawings**

17:50 to 19:20  
Auditorium II  
Juliette Allen

**Oral presentation**

**Patient characteristics and treatment outcome predictors in older adults in routine care alcohol use disorder treatment**

17:50 to 19:20  
Auditorium VI  
Silke Behrendt

**Oral presentation**

**Investigating sex and gender differences in alcohol cue-reactivity: implications for treatment strategies?**

17:50 to 19:20  
Auditorium II  
Anne Marije Kaag

**Oral presentation**

**Working elements in interventions to reduce problematic alcohol use according to older adults: a realist evaluation**

17:50 to 19:20  
Auditorium VI  
Fieke van den Bulck

**Oral presentation**

**A systematic review examining how gender and sex are measured and reported in research on alcohol treatment**

17:50 to 19:20  
Auditorium II  
Rodney Knight

**Oral presentation**

**Acute drug-toxicity presentations involving polydrug use to Euro-DEN Plus sentinel hospitals in Europe from 2014 to 2022**

17:50 to 19:20  
Room 5B  
Peter Heudtlass

**Oral presentation**

**Cannabis liberalization is only associated with increased blunt use if states lack strong tobacco control**

17:50 to 19:20  
Room 5A  
Brian Kelly

**Oral presentation**

**Cocaine use on the rise - are politicians and city level services prepared for the emerging trend of crack cocaine?**

17:50 to 19:20  
Auditorium III  
Else Kristin Utne Berg

**Oral presentation**

**Context specific factors that impact on the optimal scale up of hepatitis C testing and treatment in the UK**

17:50 to 19:20  
Auditorium IV  
Peter McCulloch

**Oral presentation**

**Data collection on acute drug toxicity using the Euro-DEN plus model in countries bordering the European Union**

17:50 to 19:20  
Room 5B  
Thomas Néfau

**Oral presentation**

**Do minimum unit pricing policies reduce alcohol harms? A review of new evidence.**

17:50 to 19:20  
Room 5A  
Cassandra Wright

**Oral presentation**

**Dual diagnosis and their care pathways for help-seeking: a multi-center study from India**

17:50 to 19:20  
Auditorium VII  
Abhishek Ghosh

**Oral presentation**

**Impact of mental health on retention in OAT**

17:50 to 19:20  
Auditorium VII  
Lucy Thi Tran

**Oral presentation**

**Inpatient admissions in people with opioid dependence: a portuguese population-**

**Oral presentation**

**Intervention development of a nature-based programme for co-occurring mental health**

**based  
observational  
retrospective  
study**

17:50 to 19:20  
Room 5B  
José Miguel Paupério

**and substance  
use problems.**

17:50 to 19:20  
Auditorium VII  
Wendy Masterton

**Oral presentation**

**Islands in the  
stream: The  
accessibility of  
mental health  
care for  
persons with  
substance use  
problems in  
Belgium**

17:50 to 19:20  
Auditorium VII  
Clara De Ruysscher

**Oral presentation**

**It is time to  
take nitrous  
oxide seriously**

17:50 to 19:20  
Room 5C  
Julaine Allan

**Oral presentation**

**Misuse of  
psychoactive  
medicines and  
its harmful  
consequences  
in Portugal**

17:50 to 19:20  
Auditorium VIII  
Ana Araújo

**Oral presentation**

**Nangs in  
Australia:  
Investigating  
nitrous oxide  
use among  
people who  
regularly use  
MDMA and/or  
other illicit  
stimulants**

17:50 to 19:20  
Room 5C  
Jodie Grigg

**Oral presentation**

**New  
challenges for  
outpatient  
care: trends  
from twenty  
years of  
monitoring  
treatment**

**Oral presentation**

**Non-Fatal  
Overdose: A  
Decade-Long  
Analysis of  
Inner-City  
Hospitals and  
Nationwide  
Trends Across**

**Oral presentation**

**Population  
aging and  
apparent  
decline in  
initiation of  
injecting drug  
use in  
Australia**

## **demand in the city of Hamburg**

17:50 to 19:20  
Room 5C  
Marcus Martens

## **Ireland (2011-2021)**

17:50 to 19:20  
Room 5B  
Jo-Hanna Ivers

17:50 to 19:20  
Room 5C  
Olivia Price

**Oral presentation**

## **Pushing the limits of tobacco control; How far can the state go in order to save us from our sins**

17:50 to 19:20  
Room 5A  
Karl Erik Lund

**Oral presentation**

## **Responding to the identification of nitazenes within the illicit diazepam market**

17:50 to 19:20  
Auditorium III  
Josie Smith

**Oral presentation**

## **Socioeconomic risk factors for long-term prescription opioid use: A national registry-linkage study**

17:50 to 19:20  
Auditorium VIII  
Ingvild Odsbu

**Oral presentation**

## **The development of a toolkit to support the elimination of viral hepatitis B and C in prisons**

17:50 to 19:20  
Auditorium IV  
Erika Duffell

**Oral presentation**

## **The impact of alcohol taxation on alcohol-attributable health inequalities in the US: a microsimulation study**

17:50 to 19:20  
Room 5A  
Carolin Kilian

**Oral presentation**

## **Towards elimination of hepatitis C in Oslo: cross-sectional prevalence studies in 2018, 2021, 2022 and 2023**

17:50 to 19:20  
Auditorium IV  
Eirik Opheim

**Oral presentation**

## **Understanding Drug Use in a Dutch Prison: A Call for Improved Research and Care and Lessons learned**

17:50 to 19:20  
Auditorium III  
Daan van der Gouwe

**Oral presentation**

**Oral presentation**

Oral presentation

**Using intensive longitudinal data to investigate predictors of cannabis and opioid use among patients with chronic pain**

17:50 to 19:20  
Auditorium VIII  
Johannes Thrul

Oral presentation

**Words vs. strands: Does the concordance of self-reported and hair-analyzed substance use of young adults change over time?**

17:50 to 19:20  
Auditorium III  
Clarissa Janousch

**Fri 25 Oct**

11:50

Oral presentation

**Effectiveness of Machine Learning Based Adjustments to an eHealth Intervention Targeting at Risk Alcohol Use**

11:50 to 13:20  
Auditorium II  
Matthijs Blankers

Oral presentation

**Identification and treatment of AUD with the 15-method - Evaluating effectiveness of the method in Danish primary care**

11:50 to 13:20  
Auditorium II  
Anette Søgaaard Nielsen

Oral presentation

**Situation in Afghanistan: Opium cultivation and heroin production**

11:50 to 13:20  
Auditorium I  
Angela Me

Oral presentation

**Substance use patterns among young homicide offenders in Finland 2002-2022**

11:50 to 13:20  
Auditorium VIII  
Anna Raeste

Oral presentation

**Homicides**

Oral presentation

**Opium and**

Oral presentation

**An exploration**



**committed by  
criminal groups  
involved in  
Swedish drug  
distribution**

11:50 to 13:20  
Auditorium VIII  
Kim Moeller

**heroin  
production in  
Southeast Asia**

11:50 to 13:20  
Auditorium I  
Bryce Pardo

**of drug  
market, gun  
violence and  
sociodemographic  
patterns in  
Stockholm  
Sweden and  
the prediction  
of gun violence**

11:50 to 13:20  
Auditorium VIII  
Mia-Maria Magnusson

**Oral presentation**

**Implications of  
heroin  
shortages in  
Europe: the  
emergence of  
synthetic  
opioids**

11:50 to 13:20  
Auditorium I  
Joanna Morais

**Oral presentation**

**Revisiting  
Goldstein: A  
New  
Framework for  
Understanding  
Drug-Related  
Violence in a  
Globalised Era**

11:50 to 13:20  
Auditorium VIII  
Marieke Liem

**Oral presentation**

**Smartphone-  
Delivered  
Cognitive Bias  
Modification  
for Reducing  
Harmful  
Drinking  
amongst  
middle - older  
age adults**

11:50 to 13:20  
Auditorium II  
Victoria Manning

**Oral presentation**

**The evolving  
situation with  
nitazenes in  
Ireland**

11:50 to 13:20  
Auditorium I  
Eamon Keenan

**Oral presentation**

**Accidental  
versus  
intentional  
drug overdose  
deaths: a  
national  
register  
linkage study**

11:50 to 13:20  
Auditorium IV  
Rebecca McDonald

**Oral presentation**

**Advancing  
Harm  
Reduction and  
Saving Lives: A  
Comprehensive  
Evaluation of  
Initiatives and  
Outcomes in  
Greece.**

11:50 to 13:20  
Room 5A  
Athanasios Theocharis

**Oral presentation**

**An online**

**Oral presentation**

**Behind the**

**Oral presentation**

**Current**

**survey of  
cannabis users  
and ex-users in  
Ireland**

11:50 to 13:20  
Room 5B  
Philip James

**frontlines:  
Exploring  
mental well-  
being and  
burnout among  
harm reduction  
workers**

11:50 to 13:20  
Room 1.07  
Katie McCormick

**perspectives  
on the  
research and  
medical use of  
psychedelic  
drugs for  
alcohol  
addiction  
treatment**

11:50 to 13:20  
Auditorium VI  
Anton Gomez-Escolar

Oral presentation

**Development  
and validation  
of the  
Problematic  
Dating App Use  
Scale  
(PRODAS):  
First results  
from a sexual  
minority cohort**

11:50 to 13:20  
Auditorium III  
Babette Lea Winter

Oral presentation

**Do Self-Report  
Drug Use  
Surveys  
Produce the  
Same Results  
in Print and  
Online Mode?  
Findings from  
a Dual Mode  
Survey.**

11:50 to 13:20  
Room 5B  
Stelios Stylianou

Oral presentation

**Drug checking:  
a harm  
reduction  
intervention to  
address the  
illicit drug  
toxicity crisis  
in a Canadian  
setting**

11:50 to 13:20  
Room 5A  
Lianping Ti

Oral presentation

**Drug use in  
French prisons.  
Results of the  
ESSPRI survey**

11:50 to 13:20  
Room 5C  
Caroline Protais

Oral presentation

**Drug-induced  
deaths and  
non-fatal  
poisonings in  
youth -  
associations  
with ACE and**

Oral presentation

**Illegal loot box  
advertising on  
social media:  
an empirical  
study using the  
Meta and  
TikTok ad**

Oral presentation

**Implementing  
trauma-  
focused  
integrated  
treatment for  
women with  
PTSD and**

## **psychiatric morbidity**

11:50 to 13:20  
Auditorium IV  
Karoliina Karjalainen

**Oral presentation**

**Needs & Modalities of Drug checking for Drug Users: Perspective of People with Lived Experience and Service Providers.**

11:50 to 13:20  
Room 5A  
Jean-Sébastien Fallu

**Oral presentation**

**Predictors of untreated remission of Internet Use Disorder in a sample of adolescents and young adults**

11:50 to 13:20

## **transparency repositories**

11:50 to 13:20  
Auditorium III  
Leon Y. Xiao

**Oral presentation**

**Online approach and characteristics of the hidden population with substance use disorder that doesn't reach treatment**

11:50 to 13:20  
Room 5B  
Ilias Paraskevopoulos

**Oral presentation**

**Prevalence of Benzodiazepine Prescription Prior to Overdose Deaths Compared to Toxicological Findings**

11:50 to 13:20

## **substance use disorder in Australia**

11:50 to 13:20  
Auditorium VII  
Shalini Arunogiri

**Oral presentation**

**Overdoses in Healthcare Workers: A thematic framework analysis of coroner reports**

11:50 to 13:20  
Room 1.07  
Thikra Algahtani

**Oral presentation**

**Posttraumatic stress disorder treatment in patients with co- substance use disorders: a randomized clinical trial**

11:50 to 13:20  
Auditorium VII  
Marleen de Waal

**Oral presentation**

**Prison-based treatment needs for people with a history of substance use disorder: A nationwide cohort study**

11:50 to 13:20

Auditorium III  
Lasse Schmidt

Auditorium IV  
Anna Armika Tussilago  
Nyman

Room 5C  
Birgitte Thylstrup

**Oral presentation**

**Psychedelic  
therapy in the  
treatment of  
addiction: the  
past, present  
and future**

11:50 to 13:20  
Auditorium VI  
Rayyan Zafar

**Oral presentation**

**Qualitative  
examination of  
coping  
motives,  
microaggression  
and  
psychological  
distress among  
bisexual+  
women  
survivors**

11:50 to 13:20  
Auditorium VII  
Gabriela Lopez

**Oral presentation**

**Relationship  
between  
parenting  
styles and  
problematic  
Internet use**

11:50 to 13:20  
Auditorium III  
Antonio Raya

**Oral presentation**

**Substance use  
and  
psychological  
states in  
imprisoned  
population in  
Greece—Key  
findings from a  
recent  
nationwide  
survey**

11:50 to 13:20  
Room 5C  
Ioulia Bafi

**Oral presentation**

**Suicide in  
people  
prescribed  
opioid-agonist  
therapy (OAT)  
in Scotland,  
2011-2020: a  
national  
retrospective  
cohort study.**

11:50 to 13:20  
Auditorium IV  
Rosalyn Fraser

**Oral presentation**

**The feasibility,  
meaningfulness,  
and  
preliminary  
effect of  
trauma  
focused  
treatment for  
drug use  
disorders in  
Denmark**

11:50 to 13:20  
Auditorium VII  
Sidsel Karsberg

**Oral presentation**

**The Mental  
Health  
Challenges  
Faced by Harm  
Reduction Staff**

11:50 to 13:20  
Room 1.07  
Laoise Darragh

**Oral presentation**

**The old kid in  
the block:  
Unpacking**

**signals of increased availability and use of ketamine**

11:50 to 13:20  
Auditorium VI  
Rita Jorge

**Oral presentation**

**The Pharmacological Management of Ketamine Use Disorder: A Systematic Review**

11:50 to 13:20  
Auditorium VI  
Emmert Roberts

**Oral presentation**

**Vicarious Trauma Among Nurses Working in Addiction Services and the Role of Leadership: A European Mixed Methods Study**

11:50 to 13:20  
Room 1.07  
K. Nicki Annunziata

**Oral presentation**

**What can we learn about poly-drug use among frequent cannabis users? results from the European Web Survey on Drugs**

11:50 to 13:20  
Room 5B  
Davide Fortin

**Oral presentation**

**What you might do versus what you actually do: measuring participant drug behaviours in drug checking services**

11:50 to 13:20  
Room 5A  
Anna Olsen

14:20

**Oral presentation**

**Gambling and global public**

**Oral presentation**

**Update on the situation in the**

**Oral presentation**

**Work related cocaine use:**

**health:  
recommendation  
from the  
Lancet Public  
Health  
Commission on  
Gambling**

14:20 to 15:50  
Auditorium I  
Heather Wardle

Oral presentation

**Measuring  
Gambling  
Harms: a  
systematic  
review and  
review of  
challenges**

14:20 to 15:50  
Auditorium I  
Louisa Degenhardt

**Netherlands  
(tbc)**

14:20 to 15:50  
Auditorium VIII  
Margriet Van Laar

Oral presentation

**Cannabis law  
reform in  
Switzerland:  
purpose,  
opportunities,  
and risks of  
local pilot  
projects**

14:20 to 15:50  
Auditorium VIII  
Frank Zobel

Oral presentation

**The Workplace  
as a “Co-  
Therapist”**

14:20 to 15:50  
Auditorium II  
Camilla Lynne Bakkeng

Oral presentation

**Gambling in  
Low and  
Middle Income  
Countries:  
evidence from  
Indonesia and  
Sub-Saharan  
Africa**

14:20 to 15:50  
Auditorium I  
Kristiana Siste

**prevalence and  
interventions**

14:20 to 15:50  
Auditorium II  
Marie-Claire Lambrechts

Oral presentation

**Issues of  
transport,  
driving safety  
&  
intoxication for  
opioid agonist  
treatment  
clients in New  
South Wales,  
Australia**

14:20 to 15:50  
Auditorium VI  
Daniel Winter

Oral presentation

**Cannabis law  
reform in  
Germany: a  
rocky road to a  
partial  
legalisation**

14:20 to 15:50  
Auditorium VIII  
Jakob Manthey

Oral presentation

**Individual  
agreements for  
recovery from  
substance  
misuse.  
Employees’  
response and  
experience of  
regulatory  
aspects.**

14:20 to 15:50

**Oral presentation**

**Physical conditions and associated health service utilization among individuals with substance-related disorders**

14:20 to 15:50  
Auditorium VI  
Christophe Huynh

**Oral presentation**

**A healthy work environment for Eastern European migrant workers in The Netherlands**

14:20 to 15:50  
Auditorium II  
Desirée Spronk

**Oral presentation**

**Cannabis law reform in Luxembourg: first observations after its change among recreational cannabis users and non-users**

14:20 to 15:50  
Auditorium VIII  
Nadine Berndt

**Oral presentation**

**Global legislative trends in gambling policy**

14:20 to 15:50  
Auditorium I  
Virve Marionneau

**Oral presentation**

**The effect of substance use disorders on vaccine uptake, acceptance, and adherence: a global systematic review**

14:20 to 15:50  
Auditorium VI  
Eva Maria Havelka

**Oral presentation**

**Out of treatment drug and alcohol users in England: ‘Unmet Treatment Need’?**

14:20 to 15:50  
Auditorium VI  
Charlie Lloyd

**Oral presentation**

**Pathways into individual substance misuse recovery agreement in the workplace**

14:20 to 15:50  
Auditorium II  
Janne Scheffels

**Oral presentation**

**The Commercial Determinants of Gambling Harms**

14:20 to 15:50  
Auditorium I  
Gerda Reith

**Oral presentation**

**Addressing Alcohol-Related Risks among Individuals with Disabilities in Sports: A Swiss Perspective**

14:20 to 15:50  
Room 5A  
Nikolai Kiselev

Oral presentation

**Are Take-Home Naloxone kits available at witnessed overdose events - a European Naloxone Outcome Research Study**

14:20 to 15:50  
Auditorium IV  
Teodora Dascal

Oral presentation

**Culturally safe addiction services: An integrated circle of care for homeless Indigenous peoples in Montréal, Canada**

14:20 to 15:50  
Room 5A  
Jessica Neicun

Oral presentation

**Development, implementation and liquidation of a national Danish Train-the-Trainer system 2010 - 2023**

14:20 to 15:50  
Auditorium IV  
Henrik Thiesen

Oral presentation

**Does Variation in Local Policy Mediate the Impact of Legal Cannabis Markets on Adolescent Cannabis Use?**

14:20 to 15:50  
Auditorium III  
Rosalie Liccardo Pacula

Oral presentation

**Drug and Alcohol Related Intoxication**

Oral presentation

**Evaluating a pilot intervention development**

Oral presentation

**Impact of Precursor Control on Drug Markets:**



## **Among Young Adolescents in Palestine**

14:20 to 15:50  
Auditorium III  
Saed Bilbaisi

## **programme utilising respiratory monitoring to prevent drug-related deaths**

14:20 to 15:50  
Auditorium IV  
Kristina Hnízdilová

## **An Expanded and Updated Systematic Review**

14:20 to 15:50  
Room 5B  
Luca Giommoni

### **Oral presentation**

## **Interventions to reduce harms related to drug use among people who experience incarceration: A systematic review**

14:20 to 15:50  
Auditorium VII  
Christel Macdonald

### **Oral presentation**

## **New processes of normalisation? Understanding changes in young people's drug use in the UK.**

14:20 to 15:50  
Auditorium III  
Harry Sumnall

### **Oral presentation**

## **PRS20: drug use and perceived mental health concerns among people living in prison in the Grand-Duchy of Luxembourg**

14:20 to 15:50  
Auditorium VII  
Tom Kugener

### **Oral presentation**

## **Radio theater-based prison artistic intervention: a mixed-method evaluation**

14:20 to 15:50  
Auditorium VII  
Isabel Silva

### **Oral presentation**

## **Spatial analysis of drug seizure events in the Golden Triangle: Findings from UNODC's Drug Monitoring**

## Platform

14:20 to 15:50  
Room 5B  
Bryce Pardo

Oral presentation

**Substance Use, Well-being, and Spiking among LGBTIQ+ and Non-LGBTIQ+ Nightlife Patrons: A Cross-Sectional Survey**

14:20 to 15:50  
Room 5A  
Ruben van Beek

Oral presentation

**The (cost-)effectiveness of contingency management for cannabis use disorder in youth: A randomized controlled trial**

14:20 to 15:50  
Auditorium III  
Eva Garssen

Oral presentation

**The impact of the 2022 ban on drug production in Afghanistan**

14:20 to 15:50  
Room 5B  
Angela Me

Oral presentation

**The impacts of cannabis legalization in the Americas: Insights from a systematic review**

14:20 to 15:50  
Room 5B  
Elle Wadsworth

Oral presentation

**The multidimensional needs and integrated service utilization patterns of youth using non-medical prescription opioids**

14:20 to 15:50  
Room 5A  
Kirsten Marchand

Oral presentation

**Who reports witnessing an opioid overdose? : Findings from the European naloxone outcome research study (NalPORS)**

14:20 to 15:50  
Auditorium IV  
Clare Mackie